BID

Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura® (Ruxolitinib) Cream in Vitiligo

Retrieved on: 
Saturday, March 18, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Inflammation, Week, The New England Journal of Medicine, Autoimmunity, American Academy, Depigmentation, Patient, AAD, BID, American Academy of Dermatology, Vitiligo, LTE, Skin, Safety, Pharmaceutical industry

The 104-week long-term extension (LTE) data build on the positive 52-week TRuE-V1 and TRuE-V2 results previously announced and published in The New England Journal of Medicine.

Key Points: 
  • The 104-week long-term extension (LTE) data build on the positive 52-week TRuE-V1 and TRuE-V2 results previously announced and published in The New England Journal of Medicine.
  • “The results presented today at AAD are significant because they provide important long-term efficacy and safety data for nonsegmental vitiligo patients treated with Opzelura,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & Autoimmunity, Incyte.
  • Approximately 29% of patients randomized to the withdrawal arm (i.e., applying vehicle cream) relapsed (
  • “Vitiligo is a chronic condition and these results demonstrate the long-term potential of this medical treatment for people with vitiligo who are interested in repigmentation.”

GLOBAL HAIKU CONTEST ATTRACTS POEMS FROM DC TO AUSTRALIA AND EVERYWHERE IN BETWEEN

Retrieved on: 
Wednesday, March 15, 2023
Haiku Society of America, Beauty, Diplomatic Reception Rooms, U.S. Department of State, Bureau, Partnership, U.S. Department of Agriculture Cotton Annex, Bureau of Educational and Cultural Affairs, State, BID, Acute and obtuse triangles, Golden Triangle, Auction, Film industry

WASHINGTON, March 15, 2023 /PRNewswire/ -- The Golden Triangle Business Improvement District (BID) today announced the winners of its 10th annual Golden Haiku contest. Selected haiku are printed on 200 colorful signs displayed along some of Washington DC's most iconic streets in the Golden Triangle neighborhood and posted on the BID website.

Key Points: 
  • More than 3,100 haiku were written by 1,600 people in Washington, DC and around the world as part of the unique downtown DC tradition to welcome spring.
  • A unique partnership with the U.S. Department of State's Bureau of Educational and Cultural Affairs helped promote the contest internationally.
  • The Golden Haiku competition follows the Haiku Society of America's guidelines for modern haiku, which does not require the traditional 5-7-5 structure.
  • The full list of winning haiku and printed signs are available on the Golden Triangle BID website .

United Corporations Limited Announces Renewal of Normal Course Issuer Bid

Retrieved on: 
Monday, March 6, 2023
Acquisition, UNC, Person, Toronto Stock Exchange, TSX, BID, Press Corporation Limited, Calendar, Exchange, Auction, Security (finance), Share (finance)

TORONTO, March 06, 2023 (GLOBE NEWSWIRE) -- United Corporations Limited (TSX:UNC) (TSX:UNC.PR.A) (TSX:UNC.PR.B) (TSX:UNC.PR.C) (the “Company”) announced today that the Toronto Stock Exchange (the “Exchange”) has accepted a notice filed by the Company of its intention to proceed with the renewal of its Normal Course Issuer Bid (the “Bid”) to be transacted through the facilities of the Exchange or through alternative Canadian trading systems.

Key Points: 
  • TORONTO, March 06, 2023 (GLOBE NEWSWIRE) -- United Corporations Limited (TSX:UNC) (TSX:UNC.PR.A) (TSX:UNC.PR.B) (TSX:UNC.PR.C) (the “Company”) announced today that the Toronto Stock Exchange (the “Exchange”) has accepted a notice filed by the Company of its intention to proceed with the renewal of its Normal Course Issuer Bid (the “Bid”) to be transacted through the facilities of the Exchange or through alternative Canadian trading systems.
  • The actual number of Shares which may be purchased pursuant to the Bid will be determined by management of the Company.
  • The funding for any purchase pursuant to the Bid will be financed out of the working capital of the Company.
  • The Company’s previous Normal Course Issuer Bid (the “Previous NCIB”) expires on March 8, 2023.

E-L Financial Corporation Limited Announces Renewal of Normal Course Issuer Bid

Retrieved on: 
Monday, March 6, 2023
Acquisition, Person, Toronto Stock Exchange, TSX, BID, Calendar, Exchange, Empire Life, Auction, Security (finance), Share (finance)

The actual number of Shares which may be purchased pursuant to the Bid will be determined by management of the Company.

Key Points: 
  • The actual number of Shares which may be purchased pursuant to the Bid will be determined by management of the Company.
  • Under the Bid, the Company may purchase up to 1,000 Shares on the Exchange during any trading day.
  • The funding for any purchase pursuant to the Bid will be financed out of the working capital of the Company.
  • The Company’s previous Normal Course Issuer Bid (the “Previous NCIB”) expires on March 8, 2023.

Economic Investment Trust Limited Announces Renewal of Normal Course Issuer Bid

Retrieved on: 
Monday, March 6, 2023
Acquisition, Person, Toronto Stock Exchange, TSX, BID, Calendar, Exchange, Auction, Security (finance), Share (finance)

TORONTO, March 06, 2023 (GLOBE NEWSWIRE) -- Economic Investment Trust Limited (TSX: EVT) (the “Company”) announced today that the Toronto Stock Exchange (the “Exchange”) has accepted a notice filed by the Company of its intention to proceed with the renewal of its Normal Course Issuer Bid (the “Bid”) to be transacted through the facilities of the Exchange or through alternative Canadian trading systems.

Key Points: 
  • TORONTO, March 06, 2023 (GLOBE NEWSWIRE) -- Economic Investment Trust Limited (TSX: EVT) (the “Company”) announced today that the Toronto Stock Exchange (the “Exchange”) has accepted a notice filed by the Company of its intention to proceed with the renewal of its Normal Course Issuer Bid (the “Bid”) to be transacted through the facilities of the Exchange or through alternative Canadian trading systems.
  • The actual number of Shares which may be purchased pursuant to the Bid will be determined by management of the Company.
  • The funding for any purchase pursuant to the Bid will be financed out of the working capital of the Company.
  • The Company’s previous Normal Course Issuer Bid (the “Previous NCIB”) expires on March 8, 2023.

Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC

Retrieved on: 
Saturday, March 4, 2023
BID, Blood pressure, Hyponatremia, Mortality, Plasma protein binding, Cleveland Clinic, Incidence, Prevalence, Obesity, Hypertension, Thought, BP, Therapy, Patient, Risk, Urinary tract infection, Congress, Target, Male, Poster, American College, Female, BMI, Aldosterone, Disease, RAAS, Safety, Glomerular filtration rate, Pharmaceutical industry

RADNOR, Pa., March 04, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced positive data from the Target-HTN Phase 2 study that demonstrated clinically meaningful blood pressure reduction with once-daily dosing of lorundrostat at the American College of Cardiology’s 72nd Annual Scientific Session together with the World Congress of Cardiology (ACC.23/WCC) going on now in New Orleans, LA. In a pre-specified analysis, hypertensive subjects with a BMI ≥30 kg/m2, demonstrated a statistically significant reduction of placebo-adjusted change in systolic blood pressure (BP) of 16.7 mmHg (p=0.002) with 50mg QD and a reduction of 12.3 mmHg (p=0.030) with 100 mg QD in Part 1 of the study.

Key Points: 
  • “We continue to be excited by the compelling data from our Target-HTN trial.
  • As rates of hypertension and obesity continue to evolve, so must our approach to treatment,” said David Rodman, M.D., Chief Medical Officer of Mineralys.
  • During ACC.23/WCC, the Company will also present Phase 1 data for lorundrostat that is included in a poster titled, “First-In-Human Study of lorundrostat, a Potent and Highly Selective Aldosterone Synthase Inhibitor”.
  • The poster will be made available on the Company’s website here on March 5, 2023.

Global Advanced Driver Assistance Systems Market Report 2022 to 2030: Featuring Continental, Magna International, Renesas Electronics and Autoliv Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 21, 2023
Automotive, Automotive Manufacturing, Technology, Other Automotive, Other Technology, Manufacturing, Hitachi, Safety, Denso, General Motors, Renesas Electronics, ADAS, BlackBerry, Magna, BMW AG, Level 3, 3D, Software, GM, Valeo, CSM, OS, MCU, Honda, Growth, BMW, Tundra, QNX, Ford Motor Company, Toyota, SOC, BID, Continental AG, Smartphone, Sale, Education minister, Audi, Continental, Component, USD, Instrumentation, Automotive industry, Mobile phone, Legend

The "Advanced Driver Assistance Systems Market by Component, by Level of Autonomy, by System Type, by Vehicle Type - Global Opportunity Analysis and Industry Forecast, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Advanced Driver Assistance Systems Market by Component, by Level of Autonomy, by System Type, by Vehicle Type - Global Opportunity Analysis and Industry Forecast, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • Also, increased adoption of integrated radar and camera systems for ADAS application drives the growth of the ADAS market.
  • For instance, in 2021 Robert Bosch Investment, Ltd. developed an automated valet parking with Hycan Automobile Technology.
  • Asia-Pacific region holds the lion's share of the global ADAS market at present, and is expected to drive the market during the forecast period.

electroCore Announces Reverse Stock Split

Retrieved on: 
Tuesday, February 14, 2023
ECOR, Panel, CUSIP, Securities and Exchange Commission (Nigeria), Security (finance), BID, Hearing, ElectroCore, Cryptocurrency

ROCKAWAY, N.J., Feb. 14, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-15.

Key Points: 
  • ROCKAWAY, N.J., Feb. 14, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-15.
  • Following the reverse stock split, the new CUSIP number of the common stock will be 28531P202, with the par value per share of common stock remaining at $0.001.
  • When the reverse stock split becomes effective, every 15 shares of the Company’s issued and outstanding common stock will be combined into one share of common stock.
  • Each stockholder’s percentage ownership interest in electroCore will remain unchanged after the reverse stock split (other than the de minimis impact from the elimination of the fractional shares).

BioXcel Therapeutics Announces Positive Full Data from Phase 2 Trial of BXCL701 in Rare, Aggressive Form of Prostate Cancer; to be Presented at 2023 ASCO Genitourinary Cancers Symposium

Retrieved on: 
Monday, February 13, 2023
Physician, Clinical Science (journal), ASCO, BID, Trial of the century, SCNC, Aes, De novo, University of California, San Francisco, Event, Pembrolizumab, Șaeș, Safety, RECIST, Phenotype, Patient, Incidence, DPP9, Artificial intelligence, AE, University, Prostate cancer, Neoplasm, Therapy, Associate, Poster, Disease, FDA, Progression-free survival, PR, Society, CTC, Publication, UCSF, Medical imaging, Pharmaceutical industry, Vaccine, HAVEN, Medicine

NEW HAVEN, Conn., Feb. 13, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced full data from its Phase 2a trial of BXCL701, the Company's investigational, oral innate immune activator, in combination with KEYTRUDA® (pembrolizumab) in small cell neuroendocrine (SCNC) variant metastatic castration-resistant prostate cancer (mCRPC) patients after at least one prior line of chemotherapy for locally advanced or metastatic prostate cancer. Results will be presented in a rapid abstract presentation and a poster presentation at the 2023 American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) Symposium on February 16, 2023.

Key Points: 
  • Results will be presented in a rapid abstract presentation and a poster presentation at the 2023 American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) Symposium on February 16, 2023.
  • In patients with RECIST 1.1-defined measurable disease (n = 25), partial response (PR) was observed in 5 (20%) patients (4 confirmed PR, 1 unconfirmed PR).
  • In 2022, there were an estimated 268,5001 new prostate cancer patients in the United States, with approximately 10,740 patients progressing to SCNC.
  • The Phase 2a trial is an open-label, multicenter study to evaluate the safety and efficacy of BXCL701 in combination with pembrolizumab in men with SCNC.

Smart for Life Provides an Update on Nasdaq Listing

Retrieved on: 
Wednesday, February 1, 2023
Wellness, Panel, Cookie, Federal Equity Rules, BID, Acquisition, Hearing, Listing Rules, Health, Ministry of Health & Wellness, News

As previously disclosed, on December 5, 2022, the Company requested a hearing with the Panel, which was held on January 19, 2023.

Key Points: 
  • As previously disclosed, on December 5, 2022, the Company requested a hearing with the Panel, which was held on January 19, 2023.
  • As a result of the Panel’s decision, the Company now has until May 30, 2023 to regain compliance with the Equity Rule and the Bid Price Rule.
  • “We are very pleased with the Panel’s decision to grant us an extension to regain compliance,” stated Darren Minton, Smart for Life’s Chief Executive Officer.
  • “We are continuing to implement our high-growth acquisition strategy and have several potential acquisitions in the pipeline.